Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

LGD-4033 and Proviron Interaction: Avoid | Peptide Database

Compound Profiles LGD-4033 Selective Androgen Receptor Modulator | Lean Mass LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its t

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

LGD-4033

Selective Androgen Receptor Modulator | Lean Mass

LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its tissue selectivity is mediated by differential cofactor recruitment: upon binding to the AR, LGD-4033 induces a receptor conformation that preferentially recruits coactivators expressed in skeletal muscle and bone, while showing minimal agonist activity in androgen-sensitive tissues such as the prostate and skin.

Proviron

DHT Derivative | Mood, Libido & Muscle Hardening

Proviron exerts its effects primarily through direct binding to the androgen receptor (AR) as a potent DHT analogue. However, its most therapeutically relevant mechanism is its exceptionally high binding affinity for sex hormone-binding globulin (SHBG).

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take LGD-4033 with Proviron?

Combining LGD-4033 with Proviron is not recommended. Both LGD-4033 and Proviron carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is LGD-4033 and Proviron safe together?

This combination carries significant risk. Both LGD-4033 and Proviron carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between LGD-4033 and Proviron?

Both LGD-4033 and Proviron carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.

How should I time LGD-4033 and Proviron?

LGD-4033 has a half-life of ~24-36 hours and Proviron has a half-life of ~12 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

What's the ideal 5/5 vs 10/3 ratio for Tesa/IPA and when to use each?

5/5 (equal parts) provides balanced GH stimulation suitable for general recovery. The 10/3 (higher tesamorelin) variant emphasizes visceral fat loss and metabolic effects. Choose 5/5 for at…

Source: peptide-db.com
comparison

BPC-157 vs TB-500: Mechanisms, Dosing & the Wolverine Stack

How BPC-157 and TB-500 compare for healing: mechanism differences, dosing protocols, clinical evidence, and when to combine both in the Wolverine Stack.

Source: peptide-db.com
comparison

Why is TB-500 dosed 2.5x higher in Tri-Heal Max versus standard Wolverine Stack?

Tri-Heal Max emphasizes TB-500's superior cell migration and angiogenesis properties (25mg vs standard 10mg) for more significant tissue damage. The 2.5:1 ratio targets acute injuries, majo…

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Community Research

Join others researching GHRP-2 — share findings, ask questions, and learn from real experiences GHRP-2 is a synthetic growth hormone secretagogue that stimulates the pituitary gland to release growth hormone. It is one of the most potent members of the GHRP family, being 2-3 times more effective than GHRP-6 in stimulating GH release. Originally developed as a diagnostic agent for growth hormone deficiency, it works by mimicking ghrelin and binding to the GHS-R1a receptor. GHRP-2 acts as a synthetic agonist of ghrelin, binding to the growth hormone secretagogue receptor (GHS-R1a) in the hypothalamus and pituitary. This stimulates cAMP production and promotes pulsatile release of endogenous growth hormone without suppressing natural feedback loops. It works synergistically with GHRH to amplify GH secretion beyond what either peptide achieves alone.

Source: peptide-db.com ↗

Research Indications

Originally FDA-approved for testosterone replacement in hypogonadal men. Fluoxymesterone was used to treat delayed puberty and androgen deficiency, though it has been almost entirely replaced by injectable testosterone and transdermal preparations due to its hepatotoxicity and unfavorable side effect profile. FDA-approved for palliative treatment of androgen-responsive, advanced inoperable breast cancer in women, typically 1-5 years post-menopause. This indication is rarely used today due to the availability of aromatase inhibitors and targeted therapies with superior safety profiles. Used by powerlifters and strength athletes in the final 2-4 weeks before a competition to maximize strength output, aggression, and neural drive without adding bodyweight or water retention. The compound's effects on the central nervous system produce a pronounced increase in competitive intensity. Employed by competitive bodybuilders in the last 2-4 weeks before stage to enhance muscle hardness, vascularity, and visual density without water retention. The non-aromatizing nature ensures no subcutaneous water accumulation during the critical final phase of contest preparation. Historically used by fighters and combat sport athletes to increase aggression and power output while staying within a weight class, as it adds no water weight. This use carries significant ethical and regulatory concerns given anti-doping testing.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Dosing Protocols

Turinabol is exclusively administered orally as a 17-alpha-alkylated steroid. It is available in tablet form, typically in 10 mg and 20 mg doses from underground laboratories. The 17-alpha-methylation provides resistance to first-pass hepatic metabolism, enabling oral bioavailability but contributing to hepatic stress. Turinabol has moderate hepatotoxicity comparable to other methylated oral steroids, and liver support supplementation is recommended during use. Its 16-hour half-life allows for once- or twice-daily dosing, though split dosing provides more stable blood levels. Performance - Conservative 30-40 mg/day Split into 2 doses (morning and evening) Oral Performance - Standard 40-60 mg/day

Source: peptide-db.com ↗
Side effects

Common Side Effects

Testosterone suppression (dose-dependent; more suppressive than Ostarine at equivalent doses, occurs in most users by week 4-6) Water retention (non-estrogenic mechanism, typically mild to moderate, contributes to scale weight increase) HDL cholesterol reduction (dose-dependent lipid impact observed in clinical trials) Headaches (most common in the first 1-2 weeks, usually transient) Fatigue or lethargy (related to testosterone suppression, typically becomes noticeable mid-cycle) Reduced libido (related to HPG axis suppression, severity varies by dose and individual)

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides